🇺🇸 Chidamide in United States
32 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 32
Most-reported reactions
- Pyrexia — 6 reports (18.75%)
- Bone Marrow Failure — 5 reports (15.62%)
- Anaemia — 3 reports (9.38%)
- Diarrhoea — 3 reports (9.38%)
- Fatigue — 3 reports (9.38%)
- Nausea — 3 reports (9.38%)
- Pneumonitis — 3 reports (9.38%)
- Acute Kidney Injury — 2 reports (6.25%)
- Arthralgia — 2 reports (6.25%)
- Blood Uric Acid Increased — 2 reports (6.25%)
Other Oncology approved in United States
Frequently asked questions
Is Chidamide approved in United States?
Chidamide does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Chidamide in United States?
Sun Yat-sen University is the originator. The local marketing authorisation holder may differ — check the official source linked above.